Stryker to acquire fluorescence imaging business Novadaq

Stryker has announced the acquisition of the Canadian fluorescence imaging technology business Novadaq.

The firm has agreed a $701 million (553.16 million pounds) deal to acquire Novadaq, which includes a net purchase price of $654 million and a net cash consideration of approximately $47 million. The deal is expected to close at the end of the third quarter.

Novadaq is a leading developer of fluorescence imaging technology that facilitates the visualisation of blood flow in vessels and related tissue perfusion in cardiac, cardiovascular, gastrointestinal, plastic, microsurgical and reconstructive procedures.

Key brands include the Spy and Pinpoint product ranges, which are utilised for breast reconstruction and colorectal surgery, as well as other minimally invasive applications.

It is expected that the purchase of Novadaq's technology will complement Stryker's advanced imaging portfolio, allowing it to expand its product offerings into the fields of open and plastic reconstructive surgery.

Timothy Scannell, group president for MedSurg and neurotechnology at Stryker, said: "Novadaq's unique innovative technology complements Stryker's advanced imaging portfolio and expands our product offerings into open and plastic reconstructive surgery."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.